Bioengineer Humans to Tackle Climate Change, Say Philosophers
By Leo Hickman,
Guardian
| 03. 14. 2012
Earlier this week, The Atlantic ran an eye-catching disturbing interview with a professor of philosophy and bioethics at New York University called S. Matthew Liao. He was invited to discuss a forthcoming paper he has co-authored which will soon be published in the journal Ethics, Policy & Environment.
But within just a few hours of the interview going live a torrent of outrage and abuse was being directed towards him online. As I tweeted at the time, the interview was indeed "unsettling". Liao explained how his paper – entitled, "Human Engineering and Climate Change" – explored the so-far-ignored subject of how "biomedical modifications of humans" could be used to "mitigate and/or adapt to climate change". The modifications discussed included: giving people drugs to make them have an adverse reaction to eating meat; making humans smaller via gene imprinting and "preimplantation genetic diagnosis"; lowering birth-rates through "cognitive enhancement"; genetically engineering eyesight to work better in the dark to help reduce the need for lighting; and the "pharmacological enhancement of altruism and empathy" to engender a...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...